Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells.
Camptothecin (CPT) and 4'-demethylepipodophyllotoxin ethylidene-beta-D-glucoside (VP16) at concentrations of 0-10 nM and 0-400 nM, respectively, have weak synergistic effects with retinoic acid (RA) on the induction of differentiation and growth inhibition of HL-60 cells. However, pretreatment of HL-60 cells with the above respective concentrations of CPT or VP16 for 1 h, had no influence on the differentiation of HL-60 cells induced by the following treatment with RA: when HL-60 cells were pretreated with CPT or VP16 at concentrations of 80 nM or 16 microM, respectively, the following treatment with RA had a synergistic effect on the induction of differentiation and growth inhibition. Morphology and biochemical markers were used to show that the differentiation-inducing effect of RA on HL-60 cells was potentiated by pretreatment with higher concentrations of 80 nM CPT or 16 microM VP16. The present results suggest that combination of CPT or VP16 at low concentration with RA or pretreatment with higher concentrations of camptothecin or VP16, followed by RA treatment may be useful for increasing the differentiation effect of RA and decreasing the side effects of RA.
Jing
Y
Y
Department of Biological Chemistry, School of Pharmaceutical Sciences, Showa University, Tokyo, Japan.
Hashimoto
S
S
Nakajo
S
S
Nakaya
K
K
D002166:Camptothecin / Q000008:administration & dosage*; D043182:Carboxylesterase; D002265:Carboxylic Ester Hydrolases / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage*; D006131:Growth Inhibitors; D006801:Humans; D066298:In Vitro Techniques; D007951:Leukemia, Myeloid / Q000201:enzymology / Q000473:pathology*; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014212:Tretinoin / Q000008:administration & dosage*; D014407:Tumor Cells, Cultured
D004273:DNA, Neoplasm; D006131:Growth Inhibitors; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014212:Tretinoin; D005047:Etoposide; D002265:Carboxylic Ester Hydrolases; D043182:Carboxylesterase; D002166:Camptothecin